Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30293
Title: Use of a buprenorphine-based pain management protocol is associated with reduced opioid requirements and pain on swallowing in oral mucositis: a retrospective cohort study.
Austin Authors: Meyer, Ilonka;Chan, Brandon;Cohen, Emma ;Dube, Esther;Hu, Raymond T C ;Yeomans, Megan;Pontonio, Frances;Heldreich, Charlotte;O'Conghaile, Stiofan ;Holmes, Natasha E ;Maroon, Nada;Weinberg, Laurence ;Tan, Chong O 
Affiliation: Pain Service
Data Analytics Research and Evaluation (DARE) Centre
Clinical Haematology
Anaesthesia
Issue Date: Jul-2022
Date: 2022
Publication information: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; 30(7): 6013-6020
Abstract: The aim of this study is to ascertain the analgesic efficacy and total oral morphine equivalent daily dose (OMEDD) effect of a buprenorphine-based analgesic protocol in the treatment of severe Oral Mucositis (OM). This is a retrospective cohort study. This study was done in a single Quaternary Referral Centre, Haematology Unit. Fifty-four stem cell transplant patients suffering at least grade 3 oral mucositis (OM), 24 prior to [Pr-I] and 30 subsequent to [Po-I] a buprenorphine-based OM analgesic protocol. We analysed data from the above subjects with the primary outcome measure of difference in total OMEDDs from all opioid types and administration routes, and secondary outcome measures of area under the curve (AUC) of 11-point Numerical Rating Scale (NRS-11) pain assessments, sedation scores and respiratory rate. Post-protocol patients' total OMEDD requirements were significantly reduced [Pr-I: 1961 (1365)mg; Po-I: 928 (625)mg, p = 0.02], as were total NRS-11:hours AUC on swallowing [Pr-I: 54(24) score-hours; Po-I: 41(18) score-hours, p < 0.001]. There were no significant differences in objective measures of OM severity between groups (Number of Grade 3 or 4 OM severity assessments [mean (SD)] Pr-I: 5 (6.2); Po-I: 7 (5.1) or number of days Neutrophil count 0.0 or 0.1 × 109/L; Pr-I: 13 (5.4); Po-I: 15 (4.7)). 5 Pr-I and 4 Po-I patients required ketamine infusions, with 1 Pr-I patient also requiring IV lignocaine. Use of Buprenorphine via transdermal, sublingual and intravenous Patient Controlled Analgesia (PCA) delivery as part of an analgesic protocol for severe post stem cell transplant oral mucositis in adult patients appears to significantly reduce opioid requirements and pain on swallowing. Further randomised prospective work is required to confirm these associations.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30293
DOI: 10.1007/s00520-022-07014-5
ORCID: 0000-0002-8025-9519
0000-0002-0169-0600
0000-0003-2423-9385
0000-0003-1161-8239
0000-0002-2194-9915
0000-0001-8501-4054
0000-0001-7403-7680
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
PubMed URL: 35403901
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35403901/
Type: Journal Article
Subjects: Acute pain
Buprenorphine
Cancer pain
Opioid
Oral mucositis
Stem cell transplant
Appears in Collections:Journal articles

Show full item record

Page view(s)

36
checked on Jun 16, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.